Cargando…

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2. OBJECTIVE: We aimed to determine the safety, tolerability, and bioavailability of 1.5% ruxolitinib cream under maximum-use conditions in patients with atopic dermatitis. Efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bissonnette, Robert, Call, Robert S., Raoof, Tooraj, Zhu, Zhaoyin, Yeleswaram, Swamy, Gong, Xiaohua, Lee, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142470/ https://www.ncbi.nlm.nih.gov/pubmed/35368221 http://dx.doi.org/10.1007/s40257-022-00690-3

Ejemplares similares

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
por: Owji, Shayan, et al.
Publicado: (2022)

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
por: Smith, Jeffrey S., et al.
Publicado: (2023)

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
por: Bloudek, Lisa, et al.
Publicado: (2022)

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
por: Yeleswaram, Swamy, et al.
Publicado: (2020)

Treatment of cutaneous lupus with topical ruxolitinib cream
por: Park, Jonathan J., et al.
Publicado: (2022)

Efficacy of Heparinoid Cream Containing Pseudo-Ceramide for Remission of Atopic Dermatitis
por: Matsuoka, Megumi, et al.
Publicado: (2021)

Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis
por: Liu, Ping, et al.
Publicado: (2016)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

The Suppressive Effect of Mamiran Cream on Atopic Dermatitis-Like Skin Lesions In Vivo
por: Aierken, Kailibinuer, et al.
Publicado: (2021)

Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis
por: Danby, Simon G., et al.
Publicado: (2022)

Atopic dermatitis in adolescence
por: Ricci, Giampaolo, et al.
Publicado: (2011)

Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?
por: Beriat, Güçlü Kaan, et al.
Publicado: (2012)

Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis
por: Huang, Chunyun, et al.
Publicado: (2014)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
por: Nugent, Shannon, et al.
Publicado: (2022)

Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment
por: Duan, M. Q., et al.
Publicado: (2023)

Tolerability and Efficacy of a Medical Device Repairing Emollient Cream in Children and Adults with Mild to Moderate Atopic Dermatitis
por: Pinter, Andreas, et al.
Publicado: (2019)

Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials
por: Bissonnette, Robert, et al.
Publicado: (2023)

Atopic dermatitis in childhood and adolescence
por: Sharma, Vinod Kumar
Publicado: (2015)

Retraction: Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis
Publicado: (2014)

A New Approach to Atopic Dermatitis Control with Low-Concentration Propolis-Loaded Cold Cream
por: Martin, Bianca Aparecida, et al.
Publicado: (2021)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Allergic Contact Dermatitis and Autoeczematization to Proctosedyl® Cream and Proctomyxin® Cream
por: Hughes, J.D. Matthew, et al.
Publicado: (2018)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
por: Khang, Juna, et al.
Publicado: (2023)

Adult-onset Atopic Dermatitis
por: Kanwar, Amrinder Jit
Publicado: (2016)

Prevalence of atopic dermatitis in adults()
por: Angles, Maria Valeria, et al.
Publicado: (2022)

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
por: Gong, Xiaohua, et al.
Publicado: (2021)

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey
por: Drucker, Aaron M., et al.
Publicado: (2022)

Medihoney Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: An Open-Label Randomized Pilot Study
por: Horev, Amir, et al.
Publicado: (2022)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
por: Fasseeh, Ahmad N., et al.
Publicado: (2022)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Mental disorders and atopic dermatitis in children and adolescents
por: Muzzolon, Mariana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i5pjmmo3v7ng3nnt6d69i8gu06